XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.2

Segments (Tables)

6 Months Ended

Jun. 30, 2023

Summary of Segment Profit

a. Segment information:

		Three months ended June 30,
		2023
		North America				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	1,991			$	1,163			$	479
Gross profit			1,046				640				254
R&D expenses			159				53				21
S&M expenses			264				194				110
G&A expenses			106				61				29
Other income			(4	)			(1	)			(28	)
Segment profit		$	520			$	334			$	124

		Three months ended June 30,
		2022
		North America				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	1,904			$	1,171			$	454
Gross profit			1,010				703				242
R&D expenses			147				56				19
S&M expenses			256				196				99
G&A expenses			127				63				30
Other income			(1	)			(1	)			(1	)
Segment profit		$	481			$	389			$	95

		Six months ended June 30,
		2023
		North America				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	3,757			$	2,347			$	971
Gross profit			1,857				1,294				517
R&D expenses			315				106				40
S&M expenses			487				381				208
G&A expenses			208				130				60
Other income			(5	)			(1	)			(29	)
Segment profit		$	852			$	679			$	237

		Six months ended June 30,
		2022
		North America				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	3,641			$	2,327			$	946
Gross profit			1,899				1,397				528
R&D expenses			289				114				39
S&M expenses			501				393				196
G&A expenses			239				122				60
Other income			(12	)			(1	)			(41	)
Segment profit		$	883			$	769			$	274

Schedule Of Consolidated Income Before Income Tax

The following table presents a reconciliation of Teva’s segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three and six months ended June 30, 2023 and 2022:

		Three months ended June 30,								Six months ended June 30,
		2023				2022				2023				2022
		(U.S. $ in millions)								(U.S. $ in millions)
North America profit		$	520			$	481			$	852			$	883
Europe profit			334				389				679				769
International Markets profit			124				95				237				274

Total reportable segments profit			977				964				1,769				1,926
Profit (loss) of other activities			33				55				27				107
Total segments profit			1,011				1,019				1,796				2,032
Amounts not allocated to segments:
Amortization			162				212				326				412
Other assets impairments, restructuring and other items			100				118				195				246
Goodwill impairment			700				745				700				745
Intangible assets impairments			63				51				241				199
Legal settlements and loss contingencies			462				729				695				1,854
Other unallocated amounts			170				113				282				240
Consolidated operating income (loss)			(646	)			(949	)			(644	)			(1,662	)
Financial expenses, net			268				211				528				468
Consolidated income (loss) before income taxes		$	(914	)		$	(1,160	)		$	(1,172	)		$	(2,131	)

b. Segment revenues by major products and activities:

Schedule of Net Sales by Product Line

The following tables present revenues by major products and activities for the three and six months ended June 30, 2023 and 2022:

North America		Three months ended June 30,
		2023				2022
		(U.S. $ in millions)
Generic products		$	969			$	1,026
AJOVY			57				49
AUSTEDO			308				204
BENDEKA® and TREANDA®			69				83
COPAXONE			64				94
Anda			392				308
Other			133				139
Total		$	1,991			$	1,904
North America		Six months ended June 30,
		2023				2022
		(U.S. $ in millions)
Generic products		$	1,793			$	1,925
AJOVY			107				86
AUSTEDO			478				358
BENDEKA and TREANDA			131				165
COPAXONE			139				180
Anda			816				650
Other			293				278
Total		$	3,757			$	3,641

Europe		Three months ended June 30,
		2023				2022
		(U.S. $ in millions)
Generic products		$	909			$	873
AJOVY			39				29
COPAXONE			60				72
Respiratory products			66				65
Other			89				131
Total		$	1,163			$	1,171
Europe		Six months ended June 30,
		2023				2022
		(U.S. $ in millions)
Generic products		$	1,841			$	1,749
AJOVY			74				60
COPAXONE			119				144
Respiratory products			134				137
Other			178				238
Total		$	2,347			$	2,327
International markets		Three months ended June 30,
		2023				2022
		(U.S. $ in millions)
Generic products		$	394			$	394
AJOVY			9				10
COPAXONE			10				9
Other			67				40
Total		$	479			$	454
International markets		Six months ended June 30,
		2023				2022
		(U.S. $ in millions)
Generic products		$	793			$	782
AJOVY			19				16
COPAXONE			22				20
Other			137				128
Total		$	971			$	946

X

- Definition

Schedule of consolidated income before income tax.

+ References

No definition available.

+ Details

Name:	teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock
Namespace Prefix:	teva_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration